



NDA 50-564/S-046  
NDA 50-720/S-018

GlaxoSmithKline  
Attention: Cynthia D'Ambrosio, Ph.D.  
Director, U.S. Regulatory Affairs  
One Franklin Plaza  
P.O. Box 7929  
Philadelphia, Pennsylvania 19101-7929

Dear Dr. D'Ambrosio:

Please refer to your supplemental new drug applications dated November 26, 2003, received November 28, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for AUGMENTIN<sup>®</sup> (amoxicillin/clavulanate potassium) Tablets, 250 mg/125mg and 500 mg/125 mg (NDA 50-564), and AUGMENTIN<sup>®</sup> (amoxicillin/clavulanate potassium) Tablets, 875 mg/125 mg (NDA 50-720). We note that these applications are subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

We acknowledge receipt of your submissions dated May 4, 2004.

These supplemental applications revise the **ADVERSE REACTIONS** section, **Renal** and **Miscellaneous** subsections, and the **OVERDOSAGE** section of the labeling to add information about the occurrence of tooth discoloration and crystalluria.

We also note the following editorial changes:

1. In the DESCRIPTION section, "hydroxypropyl methylcellulose" has been revised to read "hypromellose".
2. In the PRECAUTIONS section, Drug/Laboratory Test Interactions subsection, the reference to "Tes-Tape" has been deleted.
3. Throughout the labeling, the phrase "Augmentin tablet(s)" has been revised to read "tablet(s) of AUGMENTIN".
4. In the CONTRAINDICATIONS section, the words "Augmentin associated" have been replaced with "with AUGMENTIN" and moved to the end of the sentence.

We have completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

NDA 50-564/S-046

NDA 50-720/S-018

Page 2

The final printed labeling (FPL) must be identical to the submitted labeling (text for the package insert dated May 4, 2004), and must be formatted in accordance with the requirements of 21 CFR 201.66.

Please submit the copies of final printed labeling (FPL) electronically to each application according to the Guidance for Industry titled "Providing Regulatory Submissions in Electronic Format – NDA". Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplements NDA 50-564/S-046, and NDA 50-720/S-018." Approval of these submissions by FDA is not required before the labeling is used.

If a letter communicating important information about these drug products (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Susmita Samanta, M.D., Regulatory Project Manager, at (301) 827-2125.

Sincerely,

*{See appended electronic signature page}*

Janice M. Soreth, M.D.  
Director  
Division of Anti-Infective Drug Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Janice Soreth  
5/27/04 11:26:00 AM